Fresenius Requests Stay In Dialysis MDL To Ink Settlement

By Dani Kass (March 4, 2016, 12:25 PM EST) -- Fresenius Medical Care and plaintiffs with whom they reached a $250 million settlement in principle to end multidistrict litigation over the alleged side effects of the dialysis drugs GranuFlo and NaturaLyte on Thursday asked a Massachusetts federal judge to stay proceedings and push back trial dates while they finalize the agreement.

In a joint motion, the parties requested the stay in the 4,000-case MDL through August, giving them time to hammer out the settlement, which Fresenius announced last month. They also asked to reschedule the first two bellwether trials to October and December from February and June.

"The parties are optimistic...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!